A New Antibody Is Effective In Acute Lymphoblastic Leukemia

In adults with acute lymphoblastic leukemia, an antibody-drug conjugate helped clear hidden leukemia cells after remission.

About 70% of patients became MRD-negative, indicating a strong reduction in measurable residual disease.

Many patients remained relapse-free for more than four years.

The findings suggest targeted antibody therapy could lower relapse risk and improve long-term outcomes in ALL.